Evidence map›Paper›PMID 37569328›Full record

ArticleInternational journal of molecular sciences2023

Dihydrotanshinone Triggers Porimin-Dependent Oncosis by ROS-Mediated Mitochondrial Dysfunction in Non-Small-Cell Lung Cancer.

Dongjie Zhang, Renyikun Yuan, Jiaping Pan, Qiumei Fan, Kaili Sun, Zhipeng Xu, Xiang Gao, Qinqin Wang, Jia He, Yaqing Ye and 3 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
4.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Dongjie ZhangCollege of Basic Medical, Guangxi University of Chinese Medicine, Nanning 530200, China.
Renyikun YuanCollege of Pharmacy, Guangxi University of Chinese Medicine, Nanning 530200, China.
Jiaping PanCollege of Pharmacy, Guangxi University of Chinese Medicine, Nanning 530200, China.
Qiumei FanCollege of Pharmacy, Guangxi University of Chinese Medicine, Nanning 530200, China.
Kaili SunCollege of Pharmacy, Guangxi University of Chinese Medicine, Nanning 530200, China.
Zhipeng XuCollege of Pharmacy, Guangxi University of Chinese Medicine, Nanning 530200, China.
Xiang GaoCollege of Pharmacy, Guangxi University of Chinese Medicine, Nanning 530200, China.
Qinqin WangCollege of Pharmacy, Guangxi University of Chinese Medicine, Nanning 530200, China.
Jia HeCollege of Pharmacy, Guangxi University of Chinese Medicine, Nanning 530200, China.
Yaqing YeCollege of Basic Medical, Guangxi University of Chinese Medicine, Nanning 530200, China.
Zhengrong MuCollege of Basic Medical, Guangxi Medical University, Nanning 530200, China.
Jing LengCollege of Basic Medical, Guangxi University of Chinese Medicine, Nanning 530200, China.
Hongwei GaoCollege of Pharmacy, Guangxi University of Chinese Medicine, Nanning 530200, China.
Guangxi University of Chinese Medicine · CNGuangxi University · CNGuangxi Medical University · CN

Funding

China-ASEAN International Innovative Center for Health Industry of Traditional Chinese Medicine AD20297142Guangxi Natural Science Foundation 2018JB140265the Guangxi Science and Technology Base and Talent Special Project 2018AD19034the National Natural Science Foundation of China NSFC, 81803807, Chinathe Project of Guangxi Overseas "100 persons plan" High-level Expert, and the Project of cultivating High-level Talent Teams in the Qi Huang Project of Guangxi University of Chinese Medicine 2020002Undergraduate innovation and entrepreneurship training program S202110600120
6 · The paper itself

Abstract

Lung cancer is one of the leading causes of cancer death. Non-small-cell lung cancer (NSCLC) accounts for the majority of lung cancer diagnoses. Dihydrotanshinone (DHT) is a compound extract from

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsAdenosine TriphosphateAnimalsApoptosisCell Line, TumorHumansMiceMitochondriaReactive Oxygen SpeciesAdenosine TriphosphateReactive Oxygen Speciesdihydrotanshinonemitochondrial dysfunctionNSCLConcosisPoriminROS

Identifiers

PMID37569328
PMCPMC10419281
OpenAlexW4385357877

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.